48 results about "Monoamine oxidase B inhibitors" patented technology

The present invention relates to combinatorial therapies for treating anxiety, depression or psychotic conditions using a lithium salt and a psychoactive drug selected from the group consisting of serotonin reuptake inhibitor, a 5HT2 receptor antagonist, an anticonvulsant, a norepinephrine reuptake inhibitor, an α-adrenoreceptor antagonist, an NK-3 antagonist, an NK-1 receptor antagonist, a PDE4 inhibitor, an Neuropeptide Y5 Receptor Antagonists, a D4 receptor antagonist, a 5HT1A receptor antagonist, a 5HT1D receptor antagonist, a CRF antagonist, a monoamine oxidase inhibitor, a sedative-hypnotic drug, and an atypical antipsychotic.

The invention provides novel compounds of formula I:that are monoamine oxidase-B inhibitors, which can be useful in treating obesity, diabetes, and / or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance).

The invention discloses use of a beggarweed alkaloid monomer component. A beggarweed alkaloid monomer contains bufotenin, 5-Hydroxy-N,N-dimethyltryptamineN12-oxide and 5-methoxy-N,N-dimenthyl tryptamine. The use of the beggarweed alkaloid monomer component is used for preparing a monoamine oxidase inhibitor, namely the use in preparation of a medicament for preventing and treating depressive disorder and Parkinsonism.

The invention provides novel compounds of formulae I and II:that are monoamine oxidase-B inhibitors, which can be useful in treating obesity, diabetes, and / or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance).

Administration of a monoamine oxidase inhibitor is useful in the prevention and treatment of muscle dystrophy. Methods and compositions for inhibiting the production of reactive oxygen species in a muscle cell overproducing reactive oxygen species are provided herein.

Compositions and methods for treating, preventing, or reducing alcoholism, in particular methods for increasing patient compliance with therapies that require the intake of an ALDH inhibitor comprising the step of administering a monoamine oxidase B inhibitor.

The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, a monoamine oxidase inhibitor, a 5-HT2 antagonist or the like), and the like.

A first aspect of the invention relates to betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject. A second aspect of the invention relates to a method of treating or preventing one or more symptoms of vertigo in a subject, said method comprising administering to the subject (i) betahistine, or a pharmaceutically acceptable salt thereof, and (ii) a monoamine oxidase inhibitor.

The present disclosure relates to methods of transitioning patients or obese patients being treated with vortioxetine to treatment with a monoamine oxidase inhibitor (MAOI). The methods provided include delaying administration of the MAOI for certain time periods after stopping administration of vortioxetine. The patients or obese patients possess various capabilities of metabolizing vortioxetine. The current disclosure also includes methods of switching patients to a MAOI intended to treat psychiatric disorders while being treated with vortioxetine. The methods disclosed further comprise determining vortioxetine plasma clearance and washout time for patients with different body fat status and / or different CYP2D6 metabolizer status.

The invention discloses a purpose of a coumarin compound shown as a general formula (I) in preparation of a monoamine oxidase inhibitor, which belongs to the technical field of a medicine. Through in-vitro enzyme activity tests, the compound has good inhibition activity for monoamine oxidases A and B, and provides reference and novel thinking for developing the novel MAO inhibitor.

Selenium-containing benzobisfuran type compounds and preparation and applications thereof are disclosed. The structure formulas of the compounds are shown as a formula (X-a), a formula (X-b) and a formula (X-c), wherein R1 is a ketone group, an ester group or a cyano group, and R2 is C1-C6 alkyl, C1-C6 haloalkyl or aryl. A preparing route of the compounds is shown as follows. The compounds have good monoamine oxidase inhibitory activity and can be used for preparing monoamine oxidase inhibitors.

The invention discloses a method for synthesizing morabetamide, a novel monoamine oxidase inhibitor, which uses 5-chloro-2-pyridinecarboxylic acid as a starting material, first generates 5-chloro-2-pyridinecarboxylic acid chloride through acid chloride reaction, and then After amidation reaction, 5-chloro-N-(2-hydroxyethyl)-2-pyridinecarboxamide is generated, and finally condensed with morpholine to generate morapetamide. The compound morabetamine of the present invention adopts ethanolamine, 5-chloro-2-pyridine carboxylic acid and morpholine as main raw materials to prepare the novel monoamine oxidase inhibitor morabetamide, and the raw materials are easy to obtain. The production of morabetamide by the above method has the advantages of simple operation, good product purity and high yield, and is suitable for industrialized production.

The invention discloses an application of 1,3-benzoxazolethiol-2-one compounds, which are shown as Formula (I), in preparing a monoamine oxidase inhibitor. Based upon in-vitro enzymatic activity experimental tests, it is indicated that the compounds have good inhibitory activity on both monoamine oxidase A and monoamine oxidase B; therefore, a reference and a new thought are provided and developedfor the development of the novel MAO inhibitor (monoamine oxidase inhibitor) (shown as the Description).

The invention relates to a pharmaceutical composition comprising Morinda officinalis oligosaccharide extract and a non-sugar antidepressant as active components. It is characterized in that the total content of inulin-type oligosaccharides in the extract of Morinda officinalis oligosaccharides is 50-70%, and the content of inulin-type pentameric oligosaccharides is 5-15%; non-sugar antidepressants include Monoamine oxidase inhibitor antidepressant drugs such as moclobemide, norepinephrine reuptake inhibitor antidepressant drugs such as imipramine, amitriptyline, maprotiline, doxepin, clomipa antidepressants such as fluoxetine, paroxetine, sertraline or citalopram, etc., or dual norepinephrine / selective serotonin Non-carbohydrate antidepressants of the reuptake inhibitor class, such as mirtazapine, duloxetine, venlafaxine, or desmethylvenlafaxine. The present invention also relates to the use of the pharmaceutical composition of Morinda officinalis oligosaccharide extract and a non-saccharide antidepressant drug as active ingredients in treating neuropsychiatric diseases such as depression, anxiety, and neurogenic pain.